Skip to main
BLFS

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions is a rapidly growing life science company with a strong focus on providing specialized bioproduction tools for the cell and gene therapy industry. With a projected revenue increase of 13.6% in the current quarter and 21% for the full year 2026, as well as a positive earnings per share of $0.05, BioLife Solutions shows strong financial performance. The recent acquisition by Repligen and the company's strategic focus on biopreservation media and cryopreservation workflow further solidify its position as a leader in the sector.

Bears say

BioLife Solutions is facing increasing competition in the biopreservation market, which may lead to a decline in market share and revenue growth. The company's recent acquisition by Repligen may limit potential future growth opportunities and the expected synergies may not come to fruition. Additionally, regulatory and liquidity risks may also hinder the company's growth and profitability.

BioLife Solutions (BLFS) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Hold based on their latest research and market trends.

According to 5 analysts, BioLife Solutions (BLFS) has a Hold consensus rating as of Sep 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.